BACKGROUND: Although influenza virus resistance to the neuraminidase inhibitor zanamivir is reported less frequently than is resistance to the neuraminidase inhibitor oseltamivir in clinical settings, it is unknown whether this difference is due to the limited use of zanamivir or to an inherent property of the drug. We therefore compared the prevalence of drug-resistant viruses and virus shedding in seasonal influenza virus-infected children treated with either oseltamivir or zanamivir. METHODS: Clinical specimens (throat or nasal swab) were collected from a total of 144 pediatric influenza patients during the 2005-2006, 2006-2007, 2007-2008, and 2008-2009 influenza seasons. Neuraminidase inhibitor-resistant mutants were detected among the isolated viruses by sequencing the viral hemagglutinin and neuraminidase genes. Sensitivity of the viruses to neuraminidase inhibitors was tested by neuraminidase inhibition assay. RESULTS: In oseltamivir- or zanamivir-treated influenza patients who were statistically comparable in their age distribution, vaccination history, and type or subtype of virus isolates, the virus-shedding period in zanamivir-treated patients was significantly shorter than that in oseltamivir-treated patients. Furthermore, the frequency of zanamivir-resistant viruses was significantly lower than that of oseltamivir-resistant viruses. CONCLUSION: In comparison with treatment with oseltamivir, treatment of pediatric patients with zanamivir resulted in the emergence of fewer drug-resistant influenza viruses and a shorter virus-shedding period. We conclude that zanamivir shows promise as a better therapy for pediatric influenza patients.
BACKGROUND: Although influenza virus resistance to the neuraminidase inhibitor zanamivir is reported less frequently than is resistance to the neuraminidase inhibitor oseltamivir in clinical settings, it is unknown whether this difference is due to the limited use of zanamivir or to an inherent property of the drug. We therefore compared the prevalence of drug-resistant viruses and virus shedding in seasonal influenza virus-infectedchildren treated with either oseltamivir or zanamivir. METHODS: Clinical specimens (throat or nasal swab) were collected from a total of 144 pediatric influenzapatients during the 2005-2006, 2006-2007, 2007-2008, and 2008-2009 influenza seasons. Neuraminidase inhibitor-resistant mutants were detected among the isolated viruses by sequencing the viral hemagglutinin and neuraminidase genes. Sensitivity of the viruses to neuraminidase inhibitors was tested by neuraminidase inhibition assay. RESULTS: In oseltamivir- or zanamivir-treated influenzapatients who were statistically comparable in their age distribution, vaccination history, and type or subtype of virus isolates, the virus-shedding period in zanamivir-treated patients was significantly shorter than that in oseltamivir-treated patients. Furthermore, the frequency of zanamivir-resistant viruses was significantly lower than that of oseltamivir-resistant viruses. CONCLUSION: In comparison with treatment with oseltamivir, treatment of pediatric patients with zanamivir resulted in the emergence of fewer drug-resistant influenza viruses and a shorter virus-shedding period. We conclude that zanamivir shows promise as a better therapy for pediatric influenzapatients.
Authors: Katherine A Poehling; Kathryn M Edwards; Geoffrey A Weinberg; Peter Szilagyi; Mary Allen Staat; Marika K Iwane; Carolyn B Bridges; Carlos G Grijalva; Yuwei Zhu; David I Bernstein; Guillermo Herrera; Dean Erdman; Caroline B Hall; Ranee Seither; Marie R Griffin Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Niranjan Bhat; Jennifer G Wright; Karen R Broder; Erin L Murray; Michael E Greenberg; Maleeka J Glover; Anna M Likos; Drew L Posey; Alexander Klimov; Stephen E Lindstrom; Amanda Balish; Marie-jo Medina; Teresa R Wallis; Jeannette Guarner; Christopher D Paddock; Wun-Ju Shieh; Sherif R Zaki; James J Sejvar; David K Shay; Scott A Harper; Nancy J Cox; Keiji Fukuda; Timothy M Uyeki Journal: N Engl J Med Date: 2005-12-15 Impact factor: 91.245
Authors: C Y Tai; P A Escarpe; R W Sidwell; M A Williams; W Lew; H Wu; C U Kim; D B Mendel Journal: Antimicrob Agents Chemother Date: 1998-12 Impact factor: 5.191
Authors: C U Kim; W Lew; M A Williams; H Liu; L Zhang; S Swaminathan; N Bischofberger; M S Chen; D B Mendel; C Y Tai; W G Laver; R C Stevens Journal: J Am Chem Soc Date: 1997-01-29 Impact factor: 15.419
Authors: Arnold S Monto; Jennifer L McKimm-Breschkin; Catherine Macken; Alan W Hampson; Alan Hay; Alexander Klimov; Masato Tashiro; Robert G Webster; Michelle Aymard; Frederick G Hayden; Maria Zambon Journal: Antimicrob Agents Chemother Date: 2006-07 Impact factor: 5.191
Authors: Henju Marjuki; Vasiliy P Mishin; Anton P Chesnokov; Joyce Jones; Juan A De La Cruz; Katrina Sleeman; Daisuke Tamura; Ha T Nguyen; Ho-Sheng Wu; Feng-Yee Chang; Ming-Tsan Liu; Alicia M Fry; Nancy J Cox; Julie M Villanueva; Charles T Davis; Larisa V Gubareva Journal: J Infect Dis Date: 2014-08-14 Impact factor: 5.226
Authors: Mazhar Hussain; Henry D Galvin; Tatt Y Haw; Ashley N Nutsford; Matloob Husain Journal: Infect Drug Resist Date: 2017-04-20 Impact factor: 4.003
Authors: Seoung Geun Kim; Yoon Ha Hwang; Yung Hae Shin; Sung Won Kim; Woo Sik Jung; Sung Mi Kim; Jae Min Oh; Na Young Lee; Mun Ju Kim; Kyung Soon Cho; Yeon Gyeong Park; Sang Kee Min; Chang Kyu Lee; Jun Sub Kim; Chun Kang; Joo Yeon Lee; Man Kyu Huh; Chang Hoon Kim Journal: Korean J Pediatr Date: 2013-04-22